Drugs / MK-7622
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01852110 | Oct 2013 → Apr 2016 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7622 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01852110 ↗ |
| Action | Activate | “Muscarinic acetylcholine receptor M1 positive allosteric modulator” CHEMBL4078588 ↗ |
| Modality | Small molecule | — CHEMBL4078588 ↗ |
| Route | Oral | “Single 5 mg MK-7622 capsule once daily, taken orally.” NCT01852110 ↗ |
| Target | CHRM1 | “Muscarinic acetylcholine receptor M1 positive allosteric modulator” CHEMBL4078588 ↗ |